Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
68 hedge funds and large institutions have $13.9M invested in Infinity Pharmaceuticals, Inc. in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 19 reducing their positions, and 18 closing their positions.
434% more call options, than puts
Call options by funds: $155K | Put options by funds: $29K
11% less funds holding
Funds holding: 76 → 68 (-8)
33% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 18
47% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 19
55% less capital invested
Capital invested by funds: $30.8M → $13.9M (-$16.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mariner
Overland Park,
Kansas
|
+$1.03M |
| 2 |
CC
Callan Capital
La Jolla,
California
|
+$135K |
| 3 |
Jane Street
New York
|
+$126K |
| 4 |
GC
Gratus Capital
Atlanta,
Georgia
|
+$63.2K |
| 5 |
VF
Virtu Financial
New York
|
+$56.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$2.49M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$1M |
| 3 |
BlackRock
New York
|
-$591K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$386K |
| 5 |
E
Ergoteles
New York
|
-$288K |
INFI Hedge Fund Activity: Q4 2022 in Review
68 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q4 2022, worth a combined $13.9M — down 55% from $30.8M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of INFI and 12 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 10 added.
The largest buyer was Mariner, opening a new position worth an estimated $1.03M. The largest seller was Polar Capital Holdings, cutting an estimated $2.49M.
- 68 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q4 2022, down from 76 in Q3 2022.
- Funds reported $13.9M of Infinity Pharmaceuticals, Inc. stock for Q4 2022, down 55% quarter-over-quarter.
- 12 funds opened new Infinity Pharmaceuticals, Inc. positions in Q4 2022 and 18 closed out, a net change of -6 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q4 2022 was Mariner, an estimated $1.03M added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q4 2022 was Polar Capital Holdings, an estimated $2.49M sold.
Based on aggregated 13F filings for Q4 2022.